Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Technologies, Rules Based Medicine

NanoString Technologies has hired Lianne McLean as vice president of marketing in preparation for the commercial launch of the nCounter Analysis System.
McLean joined NanoString from Applied Biosystems where she served as director of global strategic marketing in the molecular cell biology division.
Prior to Applied Biosystems, McLean spent six years at Affymetrix where she played a role in bringing whole genome expression arrays to market, building a supporting reagents business, and developing the custom and model organism array program. McLean also spent five years at Roche Molecular Diagnostics and Chiron Diagnostics marketing in vitro diagnostics tests for infectious diseases.

Rules Based Medicine this week said that Matt Zell, managing director of Equity Group Investments, has joined its board of directors in conjunction with a $25 million financing round (see related story, this issue).

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.